Breaking News

  • 9 hours ago

  • Simantini Singh Deo

Climb Bio Receives FDA Fast Track Designation For Budoprutug, An Investigational Anti-CD19 Antibody For Primary Membranous Nephropathy
Breaking News

More News

Praxis Announces Positive EMBRAVE Trial Results Showing Significant Seizure Reduction With Elsunersen In Pediatric SCN2A Epilepsy

Praxis Announces Positive EMBRAVE Trial Results Showing Significant Se...

Vaibhavi M.

ImmunityBio Addresses FDA OPDP Concerns, Strengthens Compliance And Clarifies ANKTIVA Promotional Communications

ImmunityBio Addresses FDA OPDP Concerns, Strengthens Compliance And Cl...

Vaibhavi M.

Medicus Pharma Submits Optimised Phase 2 Trial Design For Teverelix To Address Unmet Need In BPH-Related Urinary Retention

Medicus Pharma Submits Optimised Phase 2 Trial Design For Teverelix To...

Vaibhavi M.

IDEAYA Biosciences Advances Solid Tumour Treatment, First Patient Dosed In IDEAYA’s IDE574 Trial, Exploring Novel Epigenetic Therapy For Resistant Cancers

IDEAYA Biosciences Advances Solid Tumour Treatment, First Patient Dose...

Vaibhavi M.

Ad
Advertisement

Interviews & Opinions

Article

Mr. Laxmikant Tiwari On Compliance, Quality, And Shop-Floor Ops

A 26-year operations veteran argues that compliance culture isn't built in boardrooms — it's built on shop floors, through listening, root-cause disci...

FT - Mr. Laxmikant Tiwari

Read More

Article
From Compliance To Accountability: Redefining Quality Leadership With Bruno Morgado

FT - Bruno Morgado

Article
Quality Without Compromise: Lessons In Sterility, Strategy, And Leadership With Manish Bhatkar

FT - Mr. Manish Bhatkar

Article
Dr Sweta Raghavan On Building Systems That Turn Science Into Societal Impact; Kindness, Integrity, And Impact

FT - Dr Sweta Raghavan

Ad
Advertisement
Ad

Pharma Shorts